Dyne Therapeutics

Research only

DYN · Tracked drugs and regulatory events

Tracked programs

1 program

Duchenne muscular dystrophy amenable to exon 51 skipping

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseinvestors.dyne-tx.com

Sponsor describes a PMO conjugated to an antibody fragment and a January 21, 2027 FDA target.

Sponsor links the DELIVER study of DYNE-251 to NCT05524883.

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.